Biomarkers for predicting prognosis after immunotherapy of cancer

摘要

The present invention relates to a biomarker for selecting a patient for which the occurrence of accelerated tumor progression (HPD) is predicted after treatment with an immunological anticancer drug (PD-1/PD-L1). The composition of the present invention contains two selected markers (CCR7-CD45RA-, TIGIT+), and is immune to non-small cell lung cancer patients by predicting in advance the occurrence of HPD before using an immuno-anticancer agent for cancer patients, especially non-small cell lung cancer patients. Since it is possible to decide whether to use an anticancer drug, it is expected that the life expectancy can be extended by predicting a group of patients who will show a prognosis such as accelerated progression of cancer after treatment with an immune anticancer drug early and receiving customized treatment.